Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Legend Biotech $403 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Envision Healthcare and AMSURG $600 million new credit facilities
We advised the agent on an amendment including a $300 million “first out” tranche and on a new $300 million revolver
Revolution Medicines $264.5 million follow-on offering
The shares are listed on Nasdaq
Akeso HK$582 million share placement
We advised Akeso in the placement of new shares
Precigen sale of Trans Ova Genetics to URUS
We are advising Precigen on the transaction
Acutus Medical sale of its left-heart access portfolio products and refinancing
We advised Acutus Medical on the transactions
Gracell Biotechnologies at-the-market offering
The ADSs are listed on the Nasdaq Global Select Market
Applied Therapeutics $30 million stock and warrants offering
The stock is listed on the Nasdaq Global Market
TPG Capital $1.1 billion take-private acquisition of Convey Health Solutions
We are advising TPG Capital on the transaction